Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > For the record

<< Previous

Bullboard Posts

Next >>

Comment by Canadian_101on Nov 06, 2021 10:12am

228 Views

Post# 34095553

RE:For the record

What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me something was majorly wrong when they delayed the reults, personally I cannot believe this company is still in business with the same management team in place after the horribly run trials, BUYER BEWARE is all I can say.

Justhalffull wrote: If you had invested $10,000 on Feb 7 2012, you would now have 245.87. If you need any more evidence about this outfit, you should not be investing in stocks.

<< Previous

Bullboard Posts

Next >>

Three point-of-sale stocks you should watch